Immuneering Corporation (NASDAQ:IMRX) Receives $17.75 Consensus PT from Analysts

Immuneering Corporation (NASDAQ:IMRX) has been given a consensus recommendation of “Moderate Buy” by the six research firms that are covering the company, Marketbeat.com reports. One equities research analyst has rated the stock with a sell recommendation and five have given a buy recommendation to the company. The average 12 month target price among analysts that have covered the stock in the last year is $16.40.

Several equities analysts have weighed in on IMRX shares. Oppenheimer lifted their target price on Immuneering from $21.00 to $30.00 and gave the company an “outperform” rating in a research report on Thursday, September 25th. Needham & Company LLC lifted their target price on Immuneering from $8.00 to $11.00 and gave the company a “buy” rating in a research report on Monday, September 15th. Chardan Capital lifted their target price on Immuneering from $13.00 to $20.00 and gave the company a “buy” rating in a research report on Friday, September 26th. HC Wainwright reaffirmed a “buy” rating and issued a $11.00 target price on shares of Immuneering in a research report on Tuesday. Finally, Mizuho increased their price objective on Immuneering from $8.00 to $10.00 and gave the company an “outperform” rating in a research note on Wednesday, June 18th.

Immuneering Stock Performance

Shares of IMRX stock opened at $6.36 on Monday. The firm’s 50 day moving average price is $5.58 and its 200-day moving average price is $3.31. Immuneering has a one year low of $1.10 and a one year high of $10.08. The firm has a market cap of $264.39 million, a P/E ratio of -3.37 and a beta of 0.47.

Immuneering (NASDAQ:IMRX) last issued its quarterly earnings data on Wednesday, August 13th. The company reported ($0.40) EPS for the quarter, hitting the consensus estimate of ($0.40). As a group, research analysts predict that Immuneering will post -1.86 EPS for the current fiscal year.

Insider Buying and Selling at Immuneering

In other Immuneering news, Director Peter Feinberg bought 7,500 shares of the business’s stock in a transaction dated Tuesday, September 30th. The shares were acquired at an average price of $7.03 per share, with a total value of $52,725.00. Following the transaction, the director owned 149,266 shares of the company’s stock, valued at approximately $1,049,339.98. The trade was a 5.29% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through the SEC website. Company insiders own 22.90% of the company’s stock.

Institutional Investors Weigh In On Immuneering

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Geode Capital Management LLC boosted its stake in Immuneering by 2.0% in the second quarter. Geode Capital Management LLC now owns 230,275 shares of the company’s stock valued at $776,000 after acquiring an additional 4,458 shares in the last quarter. Bridgeway Capital Management LLC grew its holdings in shares of Immuneering by 57.9% during the second quarter. Bridgeway Capital Management LLC now owns 95,449 shares of the company’s stock worth $322,000 after purchasing an additional 35,000 shares during the last quarter. HighTower Advisors LLC grew its holdings in shares of Immuneering by 17.7% during the first quarter. HighTower Advisors LLC now owns 83,960 shares of the company’s stock worth $128,000 after purchasing an additional 12,600 shares during the last quarter. Corient Private Wealth LLC purchased a new position in shares of Immuneering during the second quarter worth about $215,000. Finally, Two Sigma Investments LP grew its holdings in shares of Immuneering by 25.0% during the fourth quarter. Two Sigma Investments LP now owns 50,557 shares of the company’s stock worth $111,000 after purchasing an additional 10,126 shares during the last quarter. Institutional investors and hedge funds own 67.65% of the company’s stock.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.